Page 173 - MEMORIA ANUAL 2021

MEMORIA ANUAL 2021 SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
GEMFIN
FUNDACIÓN ESPAÑOLA DE HEMATOLOGÍA Y HEMOTERAPIA
• Unmet clinical needs in the management of CALR-mutated essential thrombo- cythaemia: a consensus-based proposal from the European Leukemia Net.
Lancet Haematol. 2021 Sep;8(9):e658-e665. doi: 10.1016/S2352-3026(21)00204-0. Álvarez-Larrán A, Sant’Antonio E, Harrison C, Kiladjian JJ, Griesshammer M, Mesa R, Ia- notto JC, Palandri F, Hernández-Boluda JC, Birgegård G, Nangalia J, Koschmieder S, Rumi E, Barbui T .
• Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed defini- tions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. Leukemia. 2021 Sep;35(9):2445-59. doi: 10.1038/s41375-021-01294-2.
McLornan DP, Hernández-Boluda JC, Czerw T, Cross N, Joachim Deeg H, Ditschkowski M, Moonim MT, Polverelli N, Robin M, Aljurf M, Conneally E, Hayden P, Yakoub-Agha I .
• Long-term follow-up of recovered MPN patients with COVID-19.
Blood Cancer J. 2021 Jun 16;11(6):115. doi: 10.1038/s41408-021-00509-0.
Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Rossi G, Harrison C, Álvarez-Larrán A, Elli EM, Kiladjian JJ, Gasior Kabat M, Marín Sánchez A, Palandri F, Andrade-Campos MM, Vannucchi AM, Carreno-Tarragona G, Papadopoulos P, Quiroz Cervantes K, Foncillas MA, Fox ML, Sagues Serrano M, Rumi E, Osorio S, Benevolo G, Patriarca A, Navas Elorza B, García-Gutiérrez V, Magro Mazo E, Lunghi F, Bonifacio M, De Stefano V, Hernández-Bolu- da JC, López Abadía E, Angona A, Xicoy Cirici B, Ruggeri M, Koschmieder S, Sobas MA, Cuevas B, Cattaneo D, Daffini R, Bellini M, Curto-García N, Garrote M, Cavalca F, Benajiba L, Bellosillo B, Guglielmelli P, Borsani O, Betti S, Salmoiraghi S, Rambaldi A .
• Determinants of survival in myelofibrosis patients undergoing allogeneic hemato- poietic cell transplantation.
Leukemia. 2021 Jan;35(1):215-24. doi: 10.1038/s41375-020-0815-z.
Hernández-Boluda JC, Pereira A, Kröger N, Beelen D, Robin M, Bornhäuser M, Angelucci E, Vitek A, Blau IW, Niittyvuopio R, Finke J, Cornelissen JJ, Passweg J, Dreger P, Petersen E, Kanz L, Sanz J, Zuckerman T, Zinger N, Iacobelli S, Hayden P, Czerw T, McLornan D, Yakoub-Agha I .
• High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib.
Leukemia. 2021 Feb;35(2):485-93. doi: 10.1038/s41375-020-01107-y.
Barbui T, Vannucchi AM, Álvarez-Larrán A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Rossi G, Elli E, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Gar- cía-Gutiérrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Boni-
173